Zacks Investment Research on MSN
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...
Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...
Stocks staged a cautious comeback as the global flight from risky assets eased, with Bitcoin halting its slide to support the ...
Several European biotechs, including Cellbox Labs, Evotec SE, Nanolive SA, and Salipro Biotech AB, have developed innovative ...
The FDA has granted accelerated approval to sevabertinib (Hyrnuo) for the treatment of patients with locally advanced or metastatic, nonsquamous non–small cell lung cancer (NS-NSCLC) with HER2 ...
Bayer (BAYRY) announced that its MEDRAD Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration ...
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 ...
Antonio Urbina, MD, the medical director for the Mount Sinai Institute for Advanced Medicine 7th Avenue clinic in New York ...
ANFarmer Ben Van Roekel discusses his experience with the Syngenta Better Yield is the Better Deal In Action trial initiative.
Discover 12 breakthrough 2025 crop innovations — from bioinsecticides to biostimulants — driving sustainability, yield, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback